Mirum Pharmaceuticals, Inc. MIRM
93.88 USD -0.73 (-0.77%)
Nov 12, 2026, 2:25 PM EST
92.13 Day range 95.06
63.23 52-week range 130.00
- YTD
- +18.85%
- 1 year
- +32.64%
News
benzinga.com Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $194 Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $184 to $194.
zacks.com MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV Mirum's brelovitug marks a second phase III win in chronic HDV, bringing the company closer to a planned 2027 BLA filing with the FDA.
reuters.com Mirum's liver infection drug lowers virus levels in second late-stage study Mirum's liver infection drug lowers virus levels in second late-stage study
businesswire.com Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD.
defenseworld.net Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $1,800,000.00 in Stock Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) CEO Christopher Peetz sold 20,000 shares of the company's stock in a transaction on Wednesday, November 4th. The shares were sold at an…
defenseworld.net Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $1,800,000.00 in Stock Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) CEO Christopher Peetz sold 20,000 shares of the company's stock in a transaction on Wednesday, November 4th. The shares were sold at an…
benzinga.com Leerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $140 Leerink Partners analyst Mani Foroohar maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $154 to $140.
businesswire.com GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing.- benzinga.com CORRECTION: RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target RBC Capital analyst Lisa Walter reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and maintains $155 price target.
benzinga.com RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target RBC Capital analyst Luca Issi reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and maintains $155 price target.
benzinga.com Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $167 Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises the price target from $144 to $167.
benzinga.com HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $202 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $200 to $202.
benzinga.com Cantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $160 Cantor Fitzgerald analyst Josh Schimmer maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $155 to $160.
benzinga.com Mirum Pharmaceuticals Q3 2026 Earnings Call Transcript Mirum Pharmaceuticals (NASDAQ:MIRM) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…- benzinga.com Mirum Pharmaceuticals Raises FY2026 Sales Guidance from $680.000M-$700.000M to $715.000M-$720.000M vs $698.093M Est Mirum Pharmaceuticals (NASDAQ:MIRM) raises FY2026 sales outlook from $680.000 million-$700.000 million to $715.000 million-$720.000 million vs $698.093 million estimate.
- benzinga.com Mirum Pharmaceuticals Q3 EPS $(0.87) Misses $(0.51) Estimate, Sales $185.721M Beat $178.078M Estimate Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.51) by 70.59 percent. This is a 1840 percent decrease over…
- benzinga.com Mirum Pharmaceuticals Announces Results From Cohort 2 Of Pivotal PROGRESS Study Of ATEBRIOZ - Zilurgisertib reduced total HO lesion volume and improved clinician-assessed joint mobility; no zilurgisertib-treated patients developed new HO lesions- Mirum plans to submit an sNDA in H1 2027 to…
benzinga.com TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $145 TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $140 to $145.- benzinga.com Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $156 Stifel analyst James Condulis maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $136 to $156.
benzinga.com Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $146 Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $146.- benzinga.com Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $152 Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $137 to $152.
- benzinga.com Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $184 Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $160 to $184.
- benzinga.com HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $200 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $195 to $200.
benzinga.com Why Is Mirum Pharmaceuticals Stock Gaining Monday? Mirum stock surges after LIVMARLI wins Phase 3 trial, showing significant itch and bile acid reduction in biliary atresia patients.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Mobile-health Network (NASDAQ:MNDR) shares increased by 141.2% to $2.05 during Monday's pre-market session. The market value of their outstanding shares is at $1.0 million. DataMEDS AI…- benzinga.com Mirum Pharmaceuticals' Phase 3 EXPAND Study Evaluating LIVMARLI Meets Primary Endpoint, Achieves Statistical Significance Across All Secondary Endpoints - Maralixibat demonstrated a statistically significant reduction in cholestatic pruritus compared with placebo (p=0.0004), and a 69% reduction in serum bile acids versus placebo (p<0.0001)- In…
- benzinga.com RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $155 RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $155.
- benzinga.com Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $160 Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $145 to $160.
- benzinga.com Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $130 Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $123 to $130.
- benzinga.com HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $195 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $140 to $195.
benzinga.com Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment The FDA approved Atebrioz by Mirum Pharmaceuticals and Incyte to treat FOP in patients aged 12 and older, reducing abnormal bone formation.- benzinga.com Mirum Pharma's Brelovitug Meets Phase 3 Primary Endpoint In AZURE-1 Study For Chronic Hepatitis Delta Virus – Phase 3 primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24– 48-week data from Phase 2b portion of AZURE-1 demonstrate deepening viral suppression and…
- benzinga.com Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and maintains $137 price target.
- benzinga.com TD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140 TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $145 to $140.
benzinga.com RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $135 RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $148 to $135.- benzinga.com Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Lowers Price Target to $137 Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and lowers the price target from $146 to $137.
- benzinga.com HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $185 to $140.
- benzinga.com CORRECTION: Mirum Pharmaceuticals Q2 Adj. EPS $(0.80) Misses $(0.68) Estimate, Sales $176.243M Beat $166.122M Estimate Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.68) by 17.65 percent. This is a 566.67 percent decrease over…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences…- benzinga.com Mirum Pharmaceuticals Raises FY2026 Sales Guidance from $660.000M-$680.000M to $680.000M-$700.000M vs $675.249M Est Mirum Pharmaceuticals (NASDAQ:MIRM) raises FY2026 sales outlook from $660.000 million-$680.000 million to $680.000 million-$700.000 million vs $675.249 million estimate.
benzinga.com RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $148 RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $142 to $148.- benzinga.com JP Morgan Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $125 JP Morgan analyst Jessica Fye maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $115 to $125.
- benzinga.com Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $146 Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises the price target from $140 to $146.
- benzinga.com Reported Sunday, Mirum Pharmaceuticals And Incyte Report Pivotal Phase 2 PROGRESS Study Results For Zilurgisertib Showing 99.9% Reduction In New HO Lesion Volume In Fibrodysplasia Ossificans Progressiva Patients At Week 24 - Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with FOP-…
- benzinga.com Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $150 Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $140 to $150.
- benzinga.com Mirum Pharmaceuticals And Incyte Announce That Phase 2 Results From The PROGRESS Study Evaluating Zilurgisertib In Patients With Fibrodysplasia Ossificans Progressiva Will Be Presented At The Endocrine Society Annual Meeting, June 13-16 The late-breaking rapid-fire presentation will include results from Cohort 1 of the placebo-controlled PROGRESS study, which enrolled patients 12 years of age and older and formed the basis of the…
- benzinga.com Citigroup Initiates Coverage On Mirum Pharmaceuticals with Buy Rating, Announces Price Target of $145 Citigroup analyst Yigal Nochomovitz initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy rating and announces Price Target of $145.
benzinga.com This Hanover Insurance Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday Wall Street analysts changed ratings on top names. Check our analyst ratings page for full updates. THG, BFRI covered.
benzinga.com This Stubhub Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. See what other analysts think of these stocks.
benzinga.com This Interface Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on OKLO, XE, MIRM, TILE, and TYRA.